Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children

Eur J Pharm Sci. 2016 Feb 15:83:1-7. doi: 10.1016/j.ejps.2015.12.002. Epub 2015 Dec 2.

Abstract

Background: 6-mercaptopurine (6-MP), a key drug for treatment of acute lymphoblastic leukemia (ALL), has until recently had no adequate formulation for pediatric patients. Several approaches have been taken but the only oral paraben-free 6-MP liquid formulation named Loulla was developed and evaluated in the target population. Preclinical and clinical evaluations were performed according to a Pediatric Investigation Plan, in order to apply for a Pediatric Use Marketing Authorization.

Methods: The pre-clinical study assessed the maximum tolerated dosage-volume and evaluated local mucosal toxicity of 28 daily administrations in treated compared to controls gold hamsters. The multi-centre clinical study was single-dose, open-label, crossover trial, conducted in 15 ALL children during maintenance therapy. The bioavailability and palatability of a single 50mg fixed dose of Loulla compared to 50mg registered tablets were evaluated in a random order on two consecutive days. Seven blood samples over 9h were obtained each day to determine 6-MP pharmacokinetic parameters, including Tmax, Cmax, AUC0-9 and AUC0-∞. A questionnaire adapted to children testing Loulla palatability and preference for either Loulla or the usual 6-MP tablet was completed. Occurrence of adverse events was determined at study visits by vital sign measurements, patient's spontaneous reporting, investigator's questioning and clinical examination.

Results: The preclinical study in gold hamsters showed that dosage-volume of 75 mg/kg/day was well tolerated. The relative bioavailability of liquid Loulla formulation compared to the reference presentation is 76% for AUC0-9 and AUC0-∞ and 80% for Cmax. The taste of Loulla and the mouth feeling after ingestion compare favorably to the tablet. No adverse event occurred.

Conclusion: Pharmacokinetic, palatability and safety data support the use of Loulla in children.

Keywords: 6-mercaptopurine; Bioavailability; Leukemia; Liquid formulation; Pediatrics; Pharmacokinetics.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / blood
  • Antimetabolites, Antineoplastic / pharmacokinetics*
  • Biological Availability
  • Chemistry, Pharmaceutical
  • Child
  • Cricetinae
  • Cross-Over Studies
  • Dosage Forms
  • Female
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Mercaptopurine / administration & dosage
  • Mercaptopurine / blood
  • Mercaptopurine / pharmacokinetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism*
  • Taste Perception
  • Young Adult

Substances

  • Antimetabolites, Antineoplastic
  • Dosage Forms
  • Mercaptopurine